Recombinant FVIIa in the management of uncontrolled hemorrhage

Transfusion

Volumn 43, Issue 12, 2003, Pages 1711-1716

  O'Connell, Niamh M ^a   Perry, David J ^b   Hodgson, Andrew J ^b   O'Shaughnessy, Denise F ^b   Laffan, Michael A ^b   Smith, Owen P ^b  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

HEMOSTATIC AGENT; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

ADULT; AGED; ARTICLE; BLEEDING; BLEEDING DISORDER; CLINICAL ARTICLE; DEATH; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEMOPHILIA; HUMAN; MALE; MORTALITY; MULTIPLE ORGAN FAILURE; RETROSPECTIVE STUDY; RISK FACTOR; SEPSIS; THROMBOEMBOLISM; THROMBOSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTIFIBRINOLYTIC AGENTS; BLOOD COMPONENT TRANSFUSION; FACTOR VIIA; FEMALE; HEMOGLOBINS; HEMORRHAGE; HEMOSTASIS; HUMANS; MALE; MIDDLE AGED; PRODUCT SURVEILLANCE, POSTMARKETING; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 0344581058     PISSN: 00411132     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.0041-1132.2003.00577.x     Document Type: Article

References (22)

1. Stainsby D, MacLennan S, Hamilton PJ. Management of massive blood loss: a template guideline. Br J Anaesth 2000;85:487-91.
2. Hedner U. NovoSeven as a universal haemostatic agent. Blood Coagul Fibrinolysis, 2000;11(Suppl 1):S107-11.
3. White B, McHale J, Ravi N, et al. Successful use of recombinant FVIIa (Novoseven) in the management of intractable post-surgical intra-abdominal haemorrhage. Br J Haematol 1999;107:677-8.
4. Hendriks HG, van der Maaten JM, de Wolf J, et al. An effective treatment of severe intractable bleeding after valve repair by one single dose of activated recombinant factor VII. Anesth Analg 2001;93:287-9.
5. Liem AK, Biesma DH, Ernst SM, Schepens AA. Recombinant activated factor VII for false aneurysms in patients with normal haemostatic mechanisms. Thromb Haemost 1999;82:150-1.
6. Vlot AJ, Ton E, Mackaay AJ, et al. Treatment of a severely bleeding patient without preexisting coagulopathy with activated recombinant factor VII. Am J Med 2000;108:421-3.
7. Tobias JD. Synthetic factor VIIa to treat dilutional coagulopathy during spinal fusion in two children. Anesthesiology 2002;96:1522-55.
8. Moscardo F, Perez F, de la Rubia J, et al. Successful treatment of severe intra-abdominal bleeding associated with disseminated intravascular coagulation using recombinant activated factor VII. Br J Haematol 2001;114:174-6.
9. Bernstein D. Effectiveness of the recombinant factor VIIa in patients with the coagulopathy of advanced child's B and C cirrhosis. Semin Thromb Hemost 2000;26:437-8.
10. Martinowitz U, Kenet G, Segal E, et al. Recombinant activated factor VII for adjunctive hemorrhage control in trauma. J Trauma 2001;51:431-8.
11. Eikelboom J, et al. Recombinant activated factor VII for massive haemorrhage in non-hemophilia patients: The Australian experience. Blood 2002;100:711a.
12. Rapaport SI. Coagulation problems in liver disease. Blood Coagul Fibrinolysis 2000;11(Suppl 1):S69-74.
13. Katz DJ, Stanley JC, Zelenock GB. Operative mortality rates for intact and ruptured abdominal aortic aneurysms in Michigan: an eleven-year statewide experience. J Vasc Surg 1994;19:804-15.
14. Basnyat PS, Biffin AH, Moseley LG, et al. Mortality from ruptured abdominal aortic aneurysm in Wales. Br J Surg 1999;86:765-70.
15. Burroughs AK, Mezzanotte G, Phillips A, et al. Cirrhotics with variceal hemorrhage: the importance of the time interval between admission and the start of analysis for survival and rebleeding rates. Hepatology 1989;9:801-7.
16. Taylor FB, Chang AC, Peer G, et al. Active site inhibited factor VIIa (DEGR VIIa) attenuates the coagulant and interleukin-6 and -8, but not tumor necrosis factor, responses of the baboon to LD100 Escherichia coli. Blood 1998;91:1609-15.
17. Carraway MS, Welty-Wolf KE, Miller DL, et al. Blockade of tissue factor: treatment for organ injury in established sepsis. Am J Respir Crit Care Med 2003;167:1200-9.
18. Santagostino E, Morfini M, Rocino A, et al. Relationship between factor VII activity and clinical efficacy of recombinant factor VIIa given by continuous infusion to patients with factor VIII inhibitors. Thromb Haemost 2001;86:954-8.
19. Ingerslev J, Sneppen O, Hvid I, et al. Treatment of acute bleeding episodes with rFVIIa. Vox Sang 1999;77(Suppl 1):42-6.
20. Hay CR, Negrier C, Ludlam CA. The treatment of bleeding in acquired hemophilia with recombinant factor VIIa: a multicentre study. Thromb Haemost 1997;78:1463-7.
21. Bevan DH. Cardiac bypass hemostasis: putting blood through the mill. Br J Haematol 1999;104:208-19.
22. Landis RC, Asimakopoulos G, Poullis M, et al. The antithrombotic and antiinflammatory mechanisms of action of aprotinin. Ann Thorac Surg 2001;72:2169-75.